


Ask a doctor about a prescription for QUETIAPINE VIATRIS 300 mg FILM-COATED TABLETS
Patient Information: Summary of Product Characteristics
Quetiapine Viatris 300 mg film-coated tablets EFG
Read this entire leaflet carefully before you start taking this medicine, as it contains important information for you.
Contents of the pack
Quetiapine Viatris contains a substance called quetiapine. It belongs to a group of medicines called antipsychotics. Quetiapine can be used to treat several diseases, such as:
Your doctor may continue to prescribe quetiapine for you even when you are feeling better.
Do not take Quetiapine Viatris:
Do not take quetiapine if any of the above applies to you. If you are in doubt, consult your doctor or pharmacist before taking quetiapine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take quetiapine if:
Tell your doctor immediatelyif, after taking quetiapine, you experience any of the following:
These disorders can be caused by this type of medicine.
Tell your doctor as soon as possible if you have:
Thoughts of suicide and worsening of your depression
If you are depressed, you may sometimes think of harming or killing yourself. This may increase when you first start treatment, as all these medicines take time to work, usually around two weeks, but sometimes more. These thoughts may also increase if you stop taking your medication abruptly. You may be more likely to think this way if you are a young adult. Clinical trial data have shown an increased risk of suicidal behavior and/or thoughts in young adults under 25 years with depression.
If you have had thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital immediately. It may be helpful to tell a relative or close friendthat you are depressed and ask them to read this leaflet. You can ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behavior.
Severe skin reactions (SCARs)
With the use of this medicine, very rare but serious skin reactions (SCARs) have been reported, which can be life-threatening or fatal. These are commonly manifested as:
If you develop these symptoms, stop using quetiapine and contact your doctor or seek medical attention immediately.
Weight gain
Weight gain has been observed in patients taking quetiapine. You and your doctor should monitor your weight regularly.
Children and adolescents
Quetiapine should not be used in children and adolescents under 18 years of age.
Other medicines and Quetiapine Viatris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Do not take quetiapine if you are using any of the following medicines:
Consult your doctor if you are using any of the following medicines:
Before stopping any of your medicines, consult your doctor first.
Taking Quetiapine Viatris with food, drinks, and alcohol
Be careful with the amount of alcohol you drink. This is because the combined effect of quetiapine and alcohol can make you drowsy.
Do not drink grapefruit juice while taking quetiapine. It may affect how the medicine works.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take quetiapine during pregnancy, unless your doctor has advised you to do so. You should not use quetiapine if you are breastfeeding.
The following symptoms, which may represent a withdrawal syndrome, may appear in newborn babies of mothers who have used quetiapine in the last trimester (last three months of their pregnancy): tremors, muscle stiffness, and/or weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your newborn develops any of these symptoms, you should contact your doctor.
Driving and using machines
These tablets may make you feel drowsy. Do not drive or use tools or machines until you know how the tablets affect you.
Quetiapine Viatris contains lactose and sodium
Quetiapine Viatris contains
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Effect on urine drug screening tests
If you are undergoing a urine drug screening test, taking quetiapine may produce positive results for methadone or certain antidepressant medicines called tricyclic antidepressants (TCAs) when some analysis methods are used, even if you are not taking methadone or TCAs. If this happens, a more specific test can be performed.
Follow the instructions for administration of this medicine exactly as prescribed by your doctor. If you are in doubt, consult your doctor or pharmacist again.
Your doctor will decide your initial dose. The maintenance dose (daily dose) will depend on your disease and needs, but it will usually be between 150 mg and 800 mg.
Liver problems
If you have liver problems, your doctor may change your dose.
Elderly people
If you are an elderly patient, your doctor may change your dose.
Use in children and adolescents
Quetiapine should not be used in children and adolescents under 18 years of age.
If you take more Quetiapine Viatris than you should
If you take more quetiapine than your doctor has prescribed, you may feel drowsy, dizzy, and experience abnormal heartbeats, dry mouth, constipation, dilated pupils, or blurred vision. Contact your doctor or the nearest hospital immediately. Take the pack and any remaining tablets with you.
You can also call the Toxicology Information Service, telephone 915620420, indicating the medicine and the amount taken.
If you forget to take a dose of Quetiapine Viatris
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, wait until then. Do not take a double dose to make up for the forgotten tablet.
If you stop taking Quetiapine Viatris
If you stop taking quetiapine abruptly, you may be unable to sleep (insomnia), feel nauseous, or experience headache, diarrhea, vomiting, dizziness, or irritability. Your doctor may suggest gradually reducing the dose before stopping treatment.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Contact a doctor IMMEDIATELY if you develop any of the following adverse effects:
Very Common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Frequency Not Known(frequency cannot be estimated from available data):
The class of medicines to which quetiapine belongs may cause heart rhythm problems that can be serious and, in severe cases, can be fatal.
Some adverse effects are only observed when a blood test is performed. These include increases in the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreases in the number of certain types of blood cells, decrease in the number of red blood cells, increase in creatine phosphokinase in the blood (a muscle substance), decrease in sodium levels in the blood, and increase in blood prolactin levels.
Your doctor may ask you to have blood tests from time to time.
Adverse Effects in Children and Adolescents:
The same adverse effects that can occur in adults can also occur in children and adolescents.
The following adverse effects have been observed more frequently in children and adolescents or have not been observed in adults:
Very Common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after CAD or EXP. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Quetiapine Viatris
The active ingredient is quetiapine fumarate.
Each film-coated tablet contains 300 mg of quetiapine (as quetiapine fumarate).
The other ingredients are: lactose monohydrate, microcrystalline cellulose (E-460), povidone 30, magnesium stearate (E-572), sodium carboxymethyl starch (type A) derived from potato starch, and calcium hydrogen phosphate dihydrate. Tablet coating: hypromellose (E-464), titanium dioxide (E-171), macrogol 400, and polysorbate 80.
Appearance of the Product and Package Contents
Quetiapine Viatris is presented in the form of film-coated tablets.
The tablets are capsule-shaped, white, with the inscription "Q" notch "300" on one face. The tablet can be divided into equal doses.
The tablets are available in blisters of 1, 3, 6, 7, 10, 14, 20, 28, 30, 50, 56, 60, 84, 90, 98, 100, 60 x 1 tablets, and in bottles of 60, 84, 90, 98, 100, 250, 500, and 1000 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
McDermott Laboratories Ltd. t/a Gerard Laboratories
35/36 Baldoyle Industrial Estate
Grange Road
Dublin 13
Ireland
Or
Generics [UK] Limited
Station Close, Potters Bar
Hertfordshire, EN6 1TL
United Kingdom
Or
Mylan Hungary Kft.
Mylan utca 1.
2900 Komáron
Hungary
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Belgium Quetiapine Viatris 300 mg film-coated tablets
Denmark Quetiapin Mylan film-coated tablets 300mg
Slovakia Quetiapin Viatris 300 mg
Spain Quetiapina Viatris 300 mg film-coated tablets EFG
Greece Quetiapine/Viatris
Iceland Quetiapin Viatris 300 mg film-coated tablets
Malta Quetiapine/VIATRIS 300 mg film-coated tablets
Netherlands Quetiapine Viatris 300 mg film-coated tablets
Portugal Quetiapina Mylan 300 mg film-coated tablets
United Kingdom (Northern Ireland) Quetiapine 300 mg film-coated tablets
Czech Republic Quetiapin Mylan
Date of the Last Revision of this Leaflet:June 2024.
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/
The average price of QUETIAPINE VIATRIS 300 mg FILM-COATED TABLETS in November, 2025 is around 97.22 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for QUETIAPINE VIATRIS 300 mg FILM-COATED TABLETS – subject to medical assessment and local rules.